RT Journal Article
SR Electronic
T1 Application of nasal spray containing dimethyl sulfoxide (DSMO) and ethanol during the COVID-19 pandemic may protect healthcare workers: A randomized controlled trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21259749
DO 10.1101/2021.07.06.21259749
A1 Ali Hosseinzadeh
A1 Mohammad Hassan Emamian
A1 Abbas Tavakolian
A1 Vahid Kia
A1 Hossein Ebrahimi
A1 Hossein Sheibani
A1 Ehsan Binesh
A1 Reza Jafari
A1 Seyed Mohammad Mirrezaie
A1 Moslem Jafarisani
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.07.06.21259749.abstract
AB Background Coronavirus pandemic has affected a large population worldwide. Currently, the standard care for individuals who are exposed is supportive care, symptomatic management, and isolation. The aim of our study was to evaluate effects of combined use of ethanol and DMSO as a nasal spray in preventing COVID-19.Methods We conducted a randomized controlled trial on volunteer healthcare workers of medical centers that were at the forefront of the fight against COVID-19 in Shahroud, Iran. Two hundred and thirty-two participants were randomly assigned to intervention and control groups to receive DSMO/ethanol or routine care, respectively. The subjects were followed for 4 weeks to determine the incidence of COVID-19 infection in each group based on the RT-qPCR test. Finally, absolute risk difference and relative risk were calculated to evaluate the effect of DSMO in prevent COVID-19.Results The results showed that the incidence of COVID-19 in the control group and intervention group were 0.07 and 0.008, respectively. The relative risk (RR) was 0.12 (0.9-0.02) according to the incidence rate in the two groups.Conclusion combined application of DSMO and ethanol in healthcare providers can considerably prevent COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRCT20200727048217NClinical Protocols https://fa.irct.ir/trial/49924 Funding StatementThis study was supported by grant No 9956 from Shahroud University of Medical Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We have an ethics committee approval cod from Shahroud University of Medical Sciences with a code of IR.SHMU.REC.1399.091.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Data will available if needed.